Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Viatris Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $20.3B | |
|---|---|---|
| Revenue (ttm) | 14.7B | |
| Net income (ttm) | -410.7M | |
| EPS (ttm) | -$0.35 | |
| Shares out | 1.1B | |
| P/E (forward) | 6.4x | |
| Dividend | $0.48 (2.54%) | |
| Volume | 5,742,185 | |
| Beta | 0.86 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.81B | $16.22B | $15.39B | $14.69B | $14.25B | -5.4% |
| Gross profit | $5.58B | $6.50B | $6.44B | $5.62B | $5.01B | -2.6% |
| Operating income | $-34.0M | $1.61B | $766.2M | $10.1M | $-2.66B | — |
| Net income | $-1.27B | $2.08B | $54.7M | $-634.2M | $-3.51B | — |
| EPS (diluted) | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 | — |
| EBITDA | $4.48B | $6.43B | $3.52B | $2.64B | $-395.4M | — |
| R&D | $751.1M | $662.2M | $805.2M | $808.7M | $965.9M | +6.5% |
| SG&A | $4.53B | $4.18B | $4.07B | $4.10B | $3.79B | -4.3% |
Recent company headlines from major financial publishers.
The Base case assumes Viatris executes on management guidance of ~2% operational revenue growth, achieving over 100 new product approvals while maintaining operating margins around 16.5% to 18.5%. Operating cash flow of approximately $2.3B supports ongoing debt reduction, yielding a Fair value of $15.91.
The Bull case envisions accelerated commercialization of complex generics and specialty pipeline assets, such as meloxicam reaching peak sales potential up to $500M. Operating margins expand substantially and rapid deleveraging drives multiple re-rating toward peer levels.
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 8.1% | $16.5 | $16.5 | $16.5 | $16.5 | $16.5 |
| 8.6% | $16.2 | $16.2 | $16.2 | $16.2 | $16.2 |
| 9.1% | $15.9 | $15.9 | $15.9 | $15.9 | $15.9 |
| 9.6% | $15.6 | $15.6 | $15.6 | $15.6 | $15.6 |
| 10.1% | $15.3 | $15.3 | $15.3 | $15.3 | $15.3 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
